Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Data from the Phase IIIb APEX study, presented at EULAR 2025, show that guselkumab (Tremfya) improved joint and skin symptoms and inhibited structural joint damage in patients with active psoriatic ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease ... Johnson's Tremfya (guselkumab), and ...

The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In ...

Upadacitinib induced clinical response in 75% and clinical remission in 56% of children with refractory Crohn's disease by week 8. The study involved 100 children, with most receiving a 45 mg ...

You should not take biologics if you have heart failure or liver disease. Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.